ZIM Laboratories, an R&D company in the pharmaceutical industry focused on developing and manufacturing differentiated products, announced an exclusive agreement in Brazil with Hypera Pharma Group, one of Brazil's largest and most diversified pharmaceutical companies. The agreement covers the exclusive marketing of VITAMIN D3 in a novel Oral Thin Film (OTF) platform with ZIM Laboratories' patented technology.
According to the agreement, ZIM Laboratories will license the developed product to COSMED for importing and marketing under HYPERA PHARMA's existing flagship brand ADDERA D3 by the name ADDERA D3 FLASH. In its OTF form, the product is intended for bone health in infants and the elderly. This unique delivery system, developed by ZIM Laboratories' patented OTF technology, will address the unserved medical needs of physicians and patients to enhance patient-adherence and convenience. Moreover, it will be preferred by the regulators for its unique features.
Commenting on the development, Dr. Anwar Daud, Chairman & Managing Director, ZIM Laboratories said, "I am very happy that our patented OTF technology is getting global recognition and acceptance. The exclusive licensing agreement with Hypera Pharma Group is a step towards ZIM Laboratories' global aspirations of becoming a preferred partner globally for new drug delivery systems."
ZIM Laboratories provides end-to-end support on product development and supplies with an intention to drive collaborative growth. It values its partnerships with the local pharmaceutical entities and is known for its strong and enduring relationships with all its partners.
Shares of Zim Laboratories Ltd was last trading in BSE at Rs.97 as compared to the previous close of Rs. 93.25. The total number of shares traded during the day was 3416 in over 58 trades.
The stock hit an intraday high of Rs. 97.8 and intraday low of 90.2. The net turnover during the day was Rs. 321930.